-
Despite 2015 slowdown, specialty continues to grow share of health spend
For the year ended May 2016, specialty medicines made up 36% of all drug spend, according to IMS Health data. And for the year-to-date as of May, specialty spending growth was at 23% — outpacing the 7.8% YTD spending growth that traditional medicines saw in the same time period.
-
Migraine may be next switch
The next big Rx-to-OTC switch opportunity in 2017 could be migraine treatments.
(To view the full Category Review, click here.)
“They did switch Imitrex [in Europe],” Laura Mahecha, industry manager healthcare for Kline Group, said, citing concerns of “potential cardiovascular side effects.” Mahecha called the potential of a 2017 migraine switch “low to moderate.”